MedKoo Cat#: 406511 | Name: IRC-083927 HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

IRC-083927 HCl is novel and potent microtubule inhibitor with potential anticancer activity. IRC-083927 inhibits the tubulin polymerization by a binding to the colchicine site. IRC-083927 inhibits in vitro cell growth of human cancer cell lines in the low nanomolar range. More interesting, it remains highly active against cell lines resistant to microtubule-interacting agents (taxanes, Vinca alkaloids, or epothilones). Chronic oral treatment with IRC-083927 (5 mg/kg) inhibits the growth of two human tumor xenografts in nude mice (C33-A, human cervical cancer and MDA-MB-231, human hormone-independent breast cancer). Together, the antitumor effects induced by IRC-083927 on tumor models resistant to tubulin agents support further investigations to fully evaluate its potential for the treatment of advanced cancers, particularly those resistant to current clinically available drugs.

Chemical Structure

IRC-083927 HCl
IRC-083927 HCl
CAS#955082-09-4

Theoretical Analysis

MedKoo Cat#: 406511

Name: IRC-083927 HCl

CAS#: 955082-09-4

Chemical Formula: C22H19FN4O4S

Exact Mass: 454.1111

Molecular Weight: 454.47

Elemental Analysis: C, 58.14; H, 4.21; F, 4.18; N, 12.33; O, 14.08; S, 7.06

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
IRC083927; IRC 083927; IRC-083927; IRC-083927 HCl; IRC-083927 hydrochloride
IUPAC/Chemical Name
Sulfamide, N-​[2-​fluoro-​4-​[4-​[2-​(phenoxymethyl)​-​1H-​imidazol-​5-​yl]​phenoxy]​phenyl]​-​, hydrochloride.
InChi Key
WDKXZCKBBNZPLY-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H19FN4O4S.ClH/c23-19-12-18(10-11-20(19)27-32(24,28)29)31-17-8-6-15(7-9-17)21-13-25-22(26-21)14-30-16-4-2-1-3-5-16;/h1-13,27H,14H2,(H,25,26)(H2,24,28,29);1H
SMILES Code
O=S(N)(NC1=CC=C(OC2=CC=C(C3=CN=C(COC4=CC=CC=C4)N3)C=C2)C=C1F)=O.[H]Cl
Appearance
white solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
        

Preparing Stock Solutions

The following data is based on the product molecular weight 454.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Chan D. Medicinal Chemistry - XXIst International Symposium. IDrugs. 2010 Nov;13(11):749-52. PubMed PMID: 21046517. 2: Liberatore AM, Coulomb H, Pons D, Dutruel O, Kasprzyk PG, Carlson M, Nelson AS, Newman SP, Stengel C, Auvray P, Hesry V, Foll B, Narboux N, Morlais D, Le Moing M, Bernetiere S, Dellile R, Camara J, Ferrandis E, Bigg DC, Prévost GP. IRC-083927 is a new tubulin binder that inhibits growth of human tumor cells resistant to standard tubulin-binding agents. Mol Cancer Ther. 2008 Aug;7(8):2426-34. doi: 10.1158/1535-7163.MCT-08-0208. Erratum in: Mol Cancer Ther. 2009 Jan;8(1):274. PubMed PMID: 18723488.